A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing dementia. That’s a potential game changer for the more than 6 million Americans diagnosed each year and the 100,000 who die from the memory-robbing disease annually.

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever. Earlier this week, Novo Nordisk tore up a partnership with the telehealth storefront Hims & Hers Health,

Danish company Novo Nordisk has launched Wegovy, its once-weekly weight-loss injection, in India as of June 24, 2025.